论文部分内容阅读
采用聚乙二醇活性酯（ＰＥＧ－５０００）化学修饰重组人白细胞介素－２（ｒＩＬ－２）及修饰后复性制得修饰产物ＰＥＧ－ｒＩＬ－２。ＰＥＧ－ｒＩＬ－２系列研究：经ＳＤＳ－ＰＡＧＥ和ＣＴＬＬ－２短期细胞培养结合３Ｈ－ＴｄＲ掺入法测定，ＰＥＧ－ｒＩＬ－２分子量为２５ｋＤ，生物活性保留６９．７％；采用ＬＤＨ释放法测定证实ＰＥＧ－ｒＩＬ－２激活的ＬＡＫ细胞对人体肝癌细胞ＢＥＬ－７４０２和Ｋ５６２细胞的杀伤作用和ｒＩＬ－２相近甚至强于ｒＩＬ－２；小鼠体内的药代动力学研究表明，经静脉给药后，ＰＥＧ－ｒＩＬ－２较ｒＩＬ－２的系统清除率降低了７．７倍，清除相半衰期延长了１２倍。提示ＰＥＧ修饰ｒＩＬ－２后可能改变目前肿瘤免疫法中ｒＩＬ－２的剂量方案，减少其用量和不良反应。
PEG-5000 was used to chemically modify recombinant human interleukin-2 (rIL-2) and modified to produce PEG-rIL-2. PEG-rIL-2 series of studies: PEG-rIL-2 molecular weight of 25kD, biological activity retained 69.7% by SDS-PAGE and CTLL-2 short-term cell culture combined with 3H-TdR incorporation assay; LDH release assay It was confirmed that the killing effect of PEG-rIL-2-activated LAK cells on human hepatocellular carcinoma cells BEL-7402 and K562 cells is similar to or even stronger than that of rIL-2. The pharmacokinetic studies in mice showed that intravenous , The system clearance rate of PEG-rIL-2 was 7.7 times lower than that of rIL-2, and the half-life of clearing phase was 12 times longer. It is suggested that PEG modified rIL-2 might change the dosage of rIL-2 in tumor immunotherapy and reduce its dosage and adverse reactions.